Luxembourg vs New Caledonia: The number of people with susceptibility test result for rifampicin
Luxembourg
21
in 2021
New Caledonia
15
in 2021
Luxembourg rank
132nd
New Caledonia rank
135th
The number of people with susceptibility test result for rifampicin over time
- Luxembourg
- New Caledonia
How they compare
Luxembourg currently reports 21 against 15 in New Caledonia, a difference of 6.
That makes Luxembourg's figure about 1.4 times New Caledonia's.
The two have swapped places 1 time across 5 shared years of data; in 2017 it was New Caledonia ahead.
Luxembourg ranks 132nd and New Caledonia ranks 135th of 155 countries.
New Caledonia has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Luxembourg | New Caledonia | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 5.33 | 21.33 | 16 | New Caledonia |
| 2020s | 19.5 | 19.5 | 0 | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher the number of people with susceptibility test result for rifampicin, Luxembourg or New Caledonia?
- Luxembourg, at 21 against 15 in New Caledonia as of 2021.
- What is the difference in the number of people with susceptibility test result for rifampicin between Luxembourg and New Caledonia?
- 6, with Luxembourg ahead.
- How many years of comparable data are there for Luxembourg and New Caledonia?
- 5 years are reported by both, from 2017 to 2021.
- How do Luxembourg and New Caledonia rank globally for the number of people with susceptibility test result for rifampicin?
- Luxembourg ranks 132nd and New Caledonia ranks 135th of 155 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients.. Statizoid refreshes it automatically from the source and publishes the full history for both places.